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Alzheimer’s disease (AD) is a multifactorial disease with a still barely understood etiology.
Herpes simplex virus 1 (HSV-1) has long been suspected to play a role in the pathogenesis of
ADbecause of its neurotropism, high rate of infection in the general population, and life-long
persistence in neuronal cells, particularly in the same brain regions that are usually altered
in AD. The goal of this study was to evaluate HSV-1-speciﬁc humoral immune responses
in patients with a diagnosis of either AD or amnestic mild cognitive impairment (aMCI),
and to verify the possible relation between HSV-1-speciﬁc antibody (Ab) titers and cortical
damage; results were compared to those obtained in a group of healthy controls (HC).
HSV-1 serum IgG titers were measured in 225 subjects (83 AD, 68 aMCI, and 74 HC).
HSV-speciﬁc Ab avidity and cortical gray matter volumes analyzed by magnetic resonance
imaging (MRI) were evaluated as well in a subgroup of these individuals (44 AD, 23 aMCI,
and 26 HC). Results showed that, whereas HSV-1 seroprevalence and IgG avidity were
comparable in the three groups, increased Ab titers (p < 0.001) were detected in AD
and aMCI compared to HC. Positive signiﬁcant correlations were detected in AD patients
alone between HSV-1 IgG titers and cortical volumes in orbitofrontal (region of interest,
ROI1 RSp0.56; p = 0.0001) and bilateral temporal cortices (ROI2 RSp0.57; p < 0.0001;
ROI3 RSp0.48; p = 0.001); no correlations could be detected between IgG avidity and MRI
parameters. Results herein suggest that a strong HSV-1-speciﬁc humoral response could
be protective toward AD-associated cortical damage.
Keywords: HSV-1, Alzheimer’s disease (AD), amnestic mild cognitive impairment (aMCI), magnetic resonance
imaging (MRI), voxel based morphometry (VBM), HSV-1 IgG
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder involv-
ing gray matter (GM) tissue that is now considered to be part
of a continuum of clinical and biological phenomena. AD is the
most common form of dementia in the elderly, affecting more
than 25 million people worldwide, with a prevalence of 5% after
65 years of age, increasing to about 30% in people aged 85 years
or older. The amnestic mild cognitive impairment (aMCI) is a
syndrome with a high risk of progression to AD, and it could con-
stitute a prodromal stage of this disorder and it represents the
borderland condition between normal aging and AD dementia
(Petersen, 2004).
Although the pathological lesions observed inAD are well char-
acterized, the causes that trigger the onset of the disease are still
unknown. Over the years many environmental and genetic com-
ponents have been hypothesized to be risk factors for this disease,
and a viral component has long been suspected to play a critical
role in the pathogenesis of AD (Honjo et al., 2009; Ball et al., 2013).
In particular, a number of experimental and epidemiological data
suggest that herpes simplex virus type 1 (HSV-1), a neurotropic
agent that is often found in elderly brain (Jamieson et al., 1991;
Wozniak et al., 2005), could have a key pathogenic role in AD (rev.
in Agostini et al., 2014).
After primary infection HSV-1 establishes a long-lasting latent
infection in the neurons of the peripheral nervous system (PNS)
within the sensory ganglia (trigeminal ganglia). External stimuli
including UV light and stress, can induce reactivation of HSV-1
from latency, an event mostly asymptomatic, or resulting in cold
sores. Serious neurological complications rarely develop and target
the same brain regions that are altered inAD (frontal and temporal
cortices as well as the hippocampus).
Although the host immune system plays an important role in
reactivating of latent HSV-1, the understanding of immunologic
control of HSV-1 in humans remains incomplete.
Recent results stemming from the analysis of the potential
role of HSV-1 speciﬁc humoral immune responses in neurode-
generation that characterize AD have shown that HSV1-speciﬁc
antibodies (IgG) titers correlate with cortical GM volume (by
voxel-based morphometry, VBM) Thus, analyses performed with
VBM in AD patients and healthy controls (HC) indicated the
presence of signiﬁcant correlations between the preservation of
temporal and orbitofrontal cortices, and higher HSV-1-speciﬁc
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antibody (Ab) titers (Mancuso et al., 2014). These data suggested
a possible protective role for HSV-1-speciﬁc humoral immunity
in those cerebral regions that are typically affected in AD as well
as in HSV-1-associated acute encephalitis.
One of the best parameters to perform a qualitative evaluation
of Abs is the measurement of avidity: the relative strength with
which Abs bind antigens. In the case of different viral infections it
is well known that multiple viral reactivation, generally occurring
throughout life, lead to stronger avidity (Thomas et al., 1996; Eisen,
2014). Recent results reported an increased HSV-1 IgG Ab avidity
index in aMCI patients compared to AD and HC (Kobayashi et al.,
2013), suggesting that viral reactivation is a particularly frequent
event in the prodromal stage of AD.
Based on these previous results we investigated whether the
correlation we detected between HSV-1-speciﬁc Ab titers and
magnetic resonance imaging (MRI) VBM parameters could be
observed in aMCI as well; possible associations between HSV-1
speciﬁc IgG avidity and preservation of brain areas were also
analyzed in a subgroup of AD and MCI patients.
MATERIALS AND METHODS
SUBJECTS
Eighty-three patients diagnosed with probable AD according to
the NINCDS–ADRDA criteria (McKhann et al., 2011), 68 subjects
diagnosed with aMCI according to Petersen criteria (Petersen,
2004) and 74 HC were included in the study. All subjects were
consecutively recruited at the Fondazione Don Gnocchi, IRCCS
in Milano, Italy. AD patients were in mild stage of the disease
as determined by both Clinical Dementia Rating (CDR; Morris,
1993) scale (CDR range 0.5–1.5) and mini-mental state exam-
ination (MMSE) score (Magni et al., 1996; MMSE mean ± SD
20.0 ± 3.0). To be eligible for the study, aMCI individuals were
required to meet the Grundman operational criteria (Grundman
et al., 2004): memory complaint, conﬁrmed by an informant;
abnormal memory function, documented by previous extensive
neuropsychological evaluation; normal general cognitive function,
as determined by both CDR scale (Morris, 1993; CDR with at least
a 0.5 in the memory domain) and MMSE (Magni et al., 1996)
score (MMSE ≥ 24); no impairment in functional activities of
daily living as determined by a clinical interview with the patient
and informant; no signiﬁcant cerebral vascular disease (Hachinski
score ≤ 4; Rosen et al., 1980); no major psychiatric illnesses with
particular attention to exclude subjects with history of depres-
sion (Hamilton Depression Rating Scale score ≤ 12; Hamilton,
1960). HC were selected according to the SENIEUR protocol for
immune-gerontological studies of European Community’s Con-
trol Action Program of Aging (Ligthart et al., 1984) and did not
have a family history of dementia or evidence of neurologic disease
at the time of enrollment. Demographic and clinical characteris-
tics of the study sample are summarized in Table 1. A subgroup
of randomly selected patients underwent advanced MRI acquisi-
tion (see MRI acquisitions and analyses for details). To increase
the diagnostic accuracy analyses of hippocampal volumes, an
index of downstream neural injury according to the guidelines
for MCI due to Alzheimer’s dementia (Sperling et al., 2011), were
also performed in the MRI study sample. The study conformed
to the ethical principles of the Helsinki Declaration; all patients
or their care-givers gave informed consent according to a proto-
col approved by the local ethics committee of the Don Gnocchi
Foundation.
IMMUNOLOGICAL ANALYSES
Herpes simplex virus 1 serum IgG titers weremeasured using com-
mercial enzyme immunoassays (BEIAHSV-1 IgG,Technogenetics,
Milano, Italy), according the attached protocol.
Brieﬂy, 100 μl of serum samples diluted (1:81) with sample
diluentwere transferred into theHSV-1 antigen coatedpolystyrene
microwells and the plates were incubated at room temperature
(RT) for 30 min. After three washing steps with washing buffer
to remove the unbound proteins, 100 μl of horseradish peroxi-
dase conjugate was added to each well and incubated at RT for
30 min. After rewashing step, 100 μl of chromogen/substrate
Table 1 | Clinical characteristics and serological results of studied subjects.
HC aMCI AD Group comparison
N = 74 N = 68 N = 83 p value
Clinical characteristics
Age (years) [median, IQR] 71.5 (63.0–77.0) 75.0 (71.0–80.0) 77.0 (73.0–80.5) p < 0.001
Gender (M:F) 32:42 31:37 33:50 n.s.
MMSE score [mean ± SD] 29.1 ± 1.7 25.5 ± 2.2 20.5 ± 3.0 p < 0.001
Level of education (years) [mean ± SD] 8.7 ± 4.2 8.9 ± 3.8 8.2 ± 3.6 n.s.
Serological results
HSV-1 seroprevalence (%) 98.6 95.6 97.6 n.s.
HSV-1 IgG titer (AI) [median, IQR] 8.0 (6.0–9.6) 8.8 (7.1–10.5) 9.3 (7.4–10.6) p < 0.001
HSV-1 avidity (%) [median, IQR]* 89.2 (85.0 – 94.6) 91.6 (86.1–96.0) 90.8 (84.6–100.0) n.s.
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; HC, healthy control; MMSE, mini mental state evaluation; IQR, interquartile range; SD, standard
deviation; HSV-1, herpes simplex virus type 1; AI, antibody index.
*A subgroup of 23 HC, 22 aMCI and 44 AD was considered.
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solution were added to each well and incubated at RT for
15 min.
Finally, 100 μl of stop solution were added to each well and the
reaction stopped. The wells were read on a plate reader (Labtech
International Ltd., UK) and optical densities (ODs) of wells were
determined at 450/620 nm. The measured absorbance is pro-
portional to the concentration of HSV-1 IgG antibodies present.
HSV-1 Ab levels were expressed as Ab index (AI), calculated by
dividing OD measurement generated from the assay by OD cut-
off calibrator. Subjects with AI >1.1 were seropositive, whereas
subjects with AI < 0.09 were seronegative.
Herpes simplex virus 1 speciﬁc IgG avidity was measured with
a protein-denaturing agent in a subgroup of seropositive subjects
(44 AD, 23 aMCI, and 26 HC); the protocol used for evalua-
tion of avidity is the same above-mentioned, with the addition
of 6 M urea to the washing solution at the washing step after
plasma reaction. The avidity index (indicated as %) was calculated
as follow: anti-HSV-1 Ab titer measured with washing includ-
ing urea/anti-HSV-1 Ab titer measured with washing without
urea.
ApoE GENOTYPING
Customer-designed Taqman probes for the 112 and 158 codons
were used to determine the genotype of apoliprotein E gene
(APOE). Primers and probes for the 112 codon are: 112 For-
ward primer: 5′-GGG CGC GGA CAT GGA G-3′; 112 Reverse
primer: 3′-TCC TCG GTG CTC TGG CC-5′; 112 Arg Probe: 5′-
CGT GCG CGG CCG-3′-FAM; 112 Cys Probe: 5′-ACG TGT GCG
GCC GCC TG-3′-VIC. Primers and probes for the 158 codon are:
158 Forward primer: 5′-TCC GCGATG CCGATG-3′; 158 Reverse
primer: 3′-GCT CGG CGC CCT CG-5′; 158 Arg probe: 5′-CCT
GCA GAA GCG CCT GGC A-3′-FAM; 158 Cys probe: 5′-CCT
GCA GAA GGG CCT GGG AGT-3′-VIC.
MRI ACQUISITIONS AND ANALYSES
MRI acquisition protocol
Brain MR images were acquired using a 1,5 T scanner
(Siemens Magnetom Avanto, Erlangen, Germany). MR exam-
ination was performed in two randomly selected subgroups
of AD HSV-1-seropositive patients and aMCI HSV-1 seropos-
itive patients. Demographic and clinical characteristics of
the subjects are summarized in Table 2. The following
sequences were acquired: (1) dual-echo turbo spin echo
(TR/TE = 2920/22 ms, FoV = 240 × 180 mm2, in-
plane resolution = 0.75 mm × 0.75 mm, slice thick-
ness = 4 mm, number of axial slices = 25) and FLAIR sequence
(TR/TE = 9000/121 ms, FoV = 240 × 168 mm2, in-plane
resolution = 0.94 mm × 0.94 mm, slice thickness = 5 mm,
number of coronal slices = 24), to exclude patients showing WM
hyperintensities outside the normal range; (2) 3-dimensional T1-
weighted magnetization prepared rapid gradient echo (MPRAGE;
TR/TE = 1900/3.37 ms, FoV = 192 mm × 256 mm, in-plane res-
olution 1 mm × 1 mm, slice thickness = 1 mm, number of axial
slices = 176), to perform VBM analysis and to calculate structural
indices.
Analysis of T1-weighted structural images
Three different analyseswere performedon theT1-weighted struc-
tural images in order to provide further information about the
underline pathology in this cohort of subjects: (1) computation of
hippocampal volumes; (2) VBM analysis; (3) Regression analysis
on a priori region of interest (ROI).
Table 2 | Demographical, neuropsychological, immunological, and anatomical information of the MRI subsample.
aMCI AD Group comparison
N = 23 N = 44 p value
Age, years (median, IQR) 76.0 [69.0–80.75] 77.5 [73–80.5] n.s.
Gender (M:F) 10:13 17:27 n.s.
Level of education (median, IQR) 8 [5–13] 8 [5–8.5] n.s.
MMSE total score (median, IQR) 25.7 [24.2–27.1] 20.6 [18.5–23.1] <0.0001
Nof APOE ε4 carriers 7 22 n.s.
HSV-1 IgG (median, IQR) 8.0 [7.2–9.7] 9.1 [7.3–10.8] n.s.
HSV-1_IgG Avidity Index, % (median, IQR) 91.6 [86.0–96.2] 90.8 [84.8–99.3] n.s.
Anatomical characteristics* (cm3)
L hippocampal volume (mean, SD) 3.08 [0.64] 2.77 [0.48] 0.025
R hippocampal volume (mean, SD) 3.18 [0.58] 2.98 [0.58] n.s.
GM volume (mean, SD) 662.46 [136.21] 653.24 [34.46] 0.001
cortical GM volume (mean, SD) 540.18 [39.66] 510.66 [30.66] 0.002
WM volume (mean, SD) 676.75 [46.71] 663.59 [33.31] n.s.
CSF volume (mean, SD) 89.81 [66.36] 85.57 [21.85] n.s.
aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; MMSE, mini mental state evaluation; HSV-1, herpes simplex virus type 1; GM, gray matter;WM,
white matter; CSF, corticospinal ﬂuid; L, left; R, right; IQR, interquartile range; SD, standard deviation.
*One-way analysis of Covariance using the volumetric scaling factor obtained with FSL-SIENAX as covariate.
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Computation of hippocampal volumes. Hippocampal volume
data were extracted for each subject from high-resolution T1 3D
images. Segmentation of right and left hippocampi was performed
using FSL’s FIRST method (Patenaude et al., 2011), an approach
combining both shape and intensity informationwithin aBayesian
model to segment subcortical structures. After hippocampal seg-
mentation, volumetric data had been obtained in each subject
using a speciﬁc FSL function.
VBM analysis. The VBM analysis was conducted using VBM81,
toolbox of SPM82, running on Matlab 7.6.03. VBM was conducted
according to the Uniﬁed Method (Ashburner and Friston, 2005).
After GM segmentation all images underwent spatial smoothing
using a Gaussian kernel (FWHM 8 mm). To identify areas with
different GM volume between the two groups direct compari-
son between AD and MCI patients was performed (two sample
t-test). Intracranial volume (ICV; obtained by adding up WM
volume + GM volume + CSF volume) entered this second level
analysis to adjust for potential confounds. Only those areas surviv-
ing 0.05 voxel-level FDR corrected threshold have been considered
as signiﬁcant.
ROI analysis. Normalized and modulated GM volumes of every
subject were computed in four 10-mm diameter spherical ROIs.
Three ROIs’ centers were located as the signiﬁcant peak obtained
with the voxel-wise correlation of GM volumes and HSV-1-
speciﬁc Ab titers in AD patients (Mancuso et al., 2014): ROI1 in
orbitofrontal cortex, ROI2 in left inferior frontal gyrus/temporal
pole, and ROI3 right inferior frontal gyrus/temporal pole. One
additional control ROI4 was positioned in dorsolateral pre-
frontal cortex, an area which is preserved by the HSV-1 and
which is affected in moderate to severe AD pathology. The
ROIs and the relative MNI coordinates were illustrated in
Figure 1A. The ROI-volumes were computed after that a thresh-
old of 0.75 was applied to the segmented GM map, in order
to increase the certainty of belonging to GM. Statistical lin-
ear regression analyses were performed between GM values in
the ROIs and HSV-1 Ab levels and IgG anti-HSV-1 antibodies
avidity.
STATISTICAL ANALYSIS
The statistical analyses were accomplished using commercial soft-
ware (SPSS for Windows, V 18.0; SPSS Inc). We compared aMCI,
AD, and HC on demographic data, using the Chi-square test and
One-wayANOVA with Bonferroni post hoc test for categorical and
continuous variables, respectively.
Differences in immunological data (HSV-1 Ab levels and IgG
anti- HSV-1 antibodies avidity) among groups where tested using
One-way ANOVA with Bonferroni post hoc test after excluding the
presence of any signiﬁcant covariate.
In a randomly selected subgroup of patients (AD, aMCI), RM-
ROI data were collected and differences between groups were
evaluated by means of MannWhitney U,Chi-square test and One-
way analysis of covariance using the volumetric scaling (V-Scaling)
1http://dbm.neuro.uni-jena.de/vbm/
2http://www.ﬁl.ion.ucl.ac.uk/spm/
3http://www.mathworks.it/products/matlab
factor obtained with FSL-SIENAX as covariate, in order to take
into account the differences in head size among subjects. Follow-
ing our previous work, GM values from ROIs of both MCI andAD
were correlated with immunological data by means of Spearman’s
correlation coefﬁcient.
All the quantitative variables were described using mean and
SD or median and interquartile range (IQR) and an alpha = 0.05
was considered signiﬁcant.
RESULTS
DEMOGRAPHICAL AND ANATOMICAL CHARACTERISTICS OF THE
PARTICIPANTS
Gender and educational levelswere similar among the three groups
(HC, aMCI, and AD). Age differed among groups (p < 0.001;
HC < AD and HC < aMCI pcorr < 0.05; AD vs. aMCI n.s.), thus
this parameter was considered as covariate in all the statistical
analyses. Global cognitive levels (MMSE) were, as per deﬁnition,
reduced in AD and aMCI compared to HC (p < 0.0001) and lower
in AD than aMCI (p < 0.0001; Table 1).
The subgroup of aMCI individuals and AD patients in whom
MRI analyses were performed were comparable for age, gender,
years of education, and proportion of APOE ε-4 carriers. Again,
a signiﬁcant difference was found for MMSE values, accordingly
with the adopted inclusion criteria (Table 2).
HSV-1 SEROPREVALENCE, TITERS, AND AVIDITY
Although no differences were observed among the groups when
HSV-1 seroprevalencewas analyzed (AD= 97.6%; aMCI= 95.6%;
HC = 98.6%),ANOVA comparisons showed that the three groups
signiﬁcantly differed with regard to HSV-1 Ab titers (p < 0.001).
Thus, signiﬁcantly higher HSV-1 IgG titers were detected in AD
(median: 9.3; range: 7.4–10.6 AI) and aMCI (median: 8.8 AI;
range: 7.1–10.5 AI) individuals compared to HC (median: 7.9 AI;
range: 6.0–9.6 AI; HC vs. AD p = 0.0049; HC vs. aMCI p = 0.025;
Figure 2).
No differences were found among the three groups when HSV-
1 IgG avidity indexes were analyzed. Thus, median HSV-1 avidity
for AD patients was 90.8% (IQR, 84.6–100.0), 91.6% (86.1–96.0)
for MCI patients, and 89.2% for HC (85.6–94.6).
As expected by the limited range of MMSE score no correla-
tions were detected between MMSE level and HSV-1 IgG titers
or avidity indices. No correlations were obtained between age,
APOE4 status and the same indices neither in the overall group
nor in the groups considered separately.
MRI RESULTS AND CORRELATIONS
Structural MRI conﬁrmed the pattern of GM atrophy typical of
aMCI and AD. In particular, left hippocampal volumes were sig-
niﬁcantly different across groups (p < 0.001), and larger in HC
compared both to MCI and AD (p < 0.001 and p = 0.02, respec-
tively), and in MCI compared to AD (p < 0.05), as shown by post
hoc tests with Bonferroni correction. Right hippocampal volumes
were signiﬁcantly different across groups as well (p < 0.001), and
were larger in HC compared both to MCI and AD (p < 0.001 and
p = 0.02, respectively) as shown by post hoc tests with Bonfer-
roni correction. No statistically signiﬁcant differences were found
between MCI and AD.
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FIGURE 1 | Region of interest (ROI) Analysis. (A) ROIs location and relative
MNI coordinates (x,y,z). (B) Scatterplots representing the correlation
between ROIs volumes of both MCI (blue circles) and AD (orange squares)
subjects vs. herpes simplex virus 1 (HSV-1)-speciﬁc Ab titers. (C) Bar charts
and error bars representing ROI volumes (mean with SEM) in the three
groups. Post hoc results are illustrated (*p < 0.05; **p < 0.01;
***p < 0.001). ROFC, right orbitofrontal cortex; LTP, left temporal lobe; RTL,
right temporal lobe; RDLPFC, right dorsolateral prefrontal cortex; AD,
Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; RSp,
Spearman correlation coefﬁcient.
Table 3 shows the results of the VBM on structural MRI data
and reveals a well-known pattern of GM atrophy in AD patients
compared to MCI patients: patients with AD were signiﬁcantly
more atrophic than aMCI subjects in several brain regions includ-
ing bilateral hippocampus and parahippocampal gyrus, right
middle temporal gyrus (right>left), right fusiform gyrus, and
right amygdala. AD patients also showed decreased GM volume
compared to aMCI subjects bilaterally in cerebellum and posterior
cingulate cortex.
Correlations between GM values from ROIs of both MCI and
AD and HSV-1-speciﬁc Ab titers are shown in Figure 1B. To sum-
marize: a statistically signiﬁcant positive correlation was detected
between AD cortical atrophy in orbitofrontal (ROI1 RSp0.56;
p = 0.0001) and bilateral temporal cortices (ROI2 RSp0.57;
p < 0.0001; ROI3 RSp0.48; p = 0.001) and HSV-1 IgG titers. Such
correlation was not observed in aMCI although areas of increased
atrophy compared with HC were seen in the bilateral temporal
cortex (Figure 1C). No correlations were obtained between the
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FIGURE 2 | Anti HSV-1 antibody (Ab) titers in healthy control, aMCI,
and AD groups. Horizontal lines represent the median value. Dotted line
represents threshold value of HSV-1 seropositivity. Statistical signiﬁcance
was evaluated using One-way ANOVA with Bonferroni correction for
multiple comparisons (signiﬁcance level: pcorr < 0.05). *Signiﬁcant
compared to aMCI and AD group vs. HC.
dorsolateral prefrontal cortex (ROI4), an areawhich is preserved in
aMCI and in mild AD, and HSV-1-speciﬁc Ab titers either. Finally,
the statistical linear regression analyses performed between GM
values in the ROIs and HSV-1 avidity index did not show any
statistically signiﬁcant differences between aMCI and AD.
DISCUSSION
A pathogenic role for HSV-1, a neurotropic agent, in AD has
long been suspected (Jamieson et al., 1991; Ball et al., 2013; Agos-
tini et al., 2014). HSV-1 induces inﬂammation in the brain areas
that are mostly affected by AD (Damasio and Van Hoesen, 1985;
Kennedy and Chaudhuri, 2002; Sokolov and Reincke, 2012), and
it contributes to senile plaque formation (Wozniak et al., 2007). In
a previous study we found a correlation between cortical atrophy
in those areas of the brain that are strongly related to pathology in
AD patients and titers of HSV-1-speciﬁc Ab, suggesting that HSV-
1-humoral immunity could be a protective factor inAD (Mancuso
et al., 2014).
Aim of the present study was to further investigate the link
between neurodegeneration and HSV-1-humoral immunity by
expanding our analyses to aMCI patients. aMCI is deﬁned as a
mild cognitive deﬁcit in the memory domain in the absence of
dementia; this condition was proposed to ﬁll the gap between nor-
mal and dementia-type pathological aging, assuming the existence
of a cognitive continuum between normal aging andAD, the main
cause of dementia (Petersen, 2004).
As expected, and conﬁrming previous data, HSV-1 seropreva-
lence did not differ when AD or aMCI patients were compared
to healthy controls (Mancuso et al., 2014). IgG Ab titers, however,
were signiﬁcantly increased in AD compared to HC, reinforcing
the borderline value of signiﬁcance found when a smaller group
of individuals was analyzed (Mancuso et al., 2014). An additional
signiﬁcant result obtained in the present study is that HSV-1 IgG
titers were signiﬁcantly increased in aMCI subjects as well. These
results are novel and suggest that this phenomenon occurs already
in the early phase of the cognitive impairment decline, before the
diagnosis of AD, and that a more robust immune response may be
elicited by HSV-1 infection in AD and aMCI subjects.
Thesedata also support thehypothesis that the alterationsof the
blood–brain barrier (BBB), a mechanism that might interact and
facilitate the effect of neurodegeneration (Carvey et al., 2009; De
Vries et al., 2012; Burgmans et al., 2013), occurs before the clinical
Table 3 |VBM results.
MNI coordinates Size Peak intensity Cortical area
x y z z value aMCI >AD*
25.5 −57 −3 129 3.07 R Parahippocampal gy/Limbic lobe
33 −19.5 −31.5 604 3.49 R Parahippocampal gy
40.5 −73.5 3 10395 4.50 R middle temporal gy
43.5 −42 −27 364 3.25 R fusiform gy
19.5 −13.5 −10.5 335 3.79 R amigdala
−22.5 22.5 −16.5 4787 4.55 L inf frontal gy/temporal pole
−52.5 −61.5 24 9975 5.18 L mid temporal gy
−18 −10.5 −9 378 3.71 L hippocampus/parahippocampus
−16.5 −27 43.5 520 3.62 L post cingulum
15 −31.5 45 184 3.23 R post cingulum
19.5 −63 48 2027 4.68 R precuneus
24 −43.5 −55.5 563 4.02 R cerebellum
−36 −81 −37.5 1381 3.88 L cerebellum
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; L, left; R, Right; gy, gyrus; mid, middle; inf, inferior; post, posterior.
*Brain areas surviving 0.05 voxel-level FDR corrected threshold with an extend cluster of 100 voxels.
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symptoms (Bäckman et al., 2005). The selective involvement of
bilateral medial temporal structures in aMCI shown with MRI
results supports this assumption. In agreement with several pre-
vious publications, the results of MRI structural data showed
that the aMCI group is midway between HC and AD patients
on the typical AD pattern of distribution of neurodegenera-
tion which starts from medial-temporal regions, then spreads to
medial-parietal cortex and orbitofrontal regions, and ﬁnally to
other neocortical association areas (Morbelli et al., 2010; Gili et al.,
2011).
Results herein also show a lack of correlation between AD cor-
tical volumes in prefrontal cortex and HSV-1 humoral immunity
and further conﬁrm the correlation between AD cortical atro-
phy in temporal and orbitofrontal cortices and HSV-1 humoral
immunity (Mancuso et al., 2014).
Given the association between brain atrophy and the increased
BBB permeability in temporal lobe of AD patients (Matsumoto
et al., 2007), it is tempting to hypothesize that concentration of
HSV-1-speciﬁc Ab in the CNS would result in down-regulation
of HSV-1 activity in those brain regions where BBB permeability
is augmented. To conﬁrm this hypothesis it will be necessary to
precisely quantify the actual titers of Ab that enter the brain when
the BBB permeability is altered.
Interestingly, such a correlation was not observed in aMCI,
even if area of increased atrophy in the temporal cortex was seen
in these individuals. The small number of aMCI analyzed as well
as the fact that not all aMCI will evolve into AD may play a
role in such ﬁndings. In fact, several studies reported that not
all individuals with MCI (amnestic or non-amnestic, including
those with positive biomarkers) progress to AD, particularly in
community-based settings, and the typical rates at which aMCI
patients progress to AD is 14–18% per year (Petersen et al., 2009;
Ganguli et al., 2011; Brodaty et al., 2013). Future studieswith larger
samples of aMCI patients, as well as a longitudinal evaluation
of the present sample will help in the comprehension of these
results.
Although several evidences indicate that HSV-1 plays a key role
in the disease (e.g., the HSV-1 speciﬁc localization in amyloid
plaques –Wozniak et al., 2009), it cannot be excluded that a robust
immune response may have a protective role against AD devel-
opment making HSV-1 suppression simply a secondary effect.
An alternative explanation could be that high Ab levels reﬂect
viral-induced host responses due to an attempt to control HSV-
1 in those affected brain regions showing an increased antigen
presentation.
To further study the relationship between HSV-1 infection
and neurodegeneration, HSV-1 avidity was also investigated in
the current study. Recently Kobayashi et al. (2013) reported that
the avidity of HSV-1-speciﬁc IgG is increased in aMCI patients
compared to HC and AD subjects, suggesting that an abnormal
rate of HSV-1 reactivation can contribute to the neurodegener-
ation process in the initial stage of dementia. Our results did
not evidence differences in the avidity of these Ab in the three
groups analyzed. Higher avidity is considered to be a marker of
recent primary infection (Odievre et al., 2002) and many studies
have shown its utility in the evaluation of immune status dur-
ing pregnancy, (Fitzgerald et al., 1988; De Ory et al., 1993; Junker
and Tilley, 1994; Boppana and Britt, 1995), as this parameter can
recognize acute infections that are associated with a high neonatal
risk. Data herein, thus, probably reﬂect that primary HSV-1 infec-
tion occurred early in life; if that is the case, clear differences about
this index are not appreciable, as already attested by Hashido et al.
(1997).
In conclusion, our analyses conﬁrm the hypothesis that the
presence of potent HSV-1-speciﬁc immune responses plays a pro-
tective role against AD-associated GM degeneration, supporting
the idea that HSV-1 might indeed play a critical role in the
pathogenesis of this disease.
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